Vaccinex (VCNX) Price & Analysis

Q: What was Vaccinex Inc’s price range in the past 12 months?

Vaccinex Inc lowest stock price was $0.25 and its highest was $4.35 in the past 12 months.

Q: What is Vaccinex Inc’s market cap?

Vaccinex Inc’s market cap is $1.34M.

Q: When is Vaccinex Inc’s upcoming earnings report date?

Vaccinex Inc’s upcoming earnings report date is Nov 17, 2025 which is 30 days ago.

Q: Is Vaccinex Inc overvalued?

According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Vaccinex Inc pay dividends?

Vaccinex Inc does not currently pay dividends.

Q: What is Vaccinex Inc’s EPS estimate?

Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Vaccinex Inc have?

Vaccinex Inc has 2,676,637 shares outstanding.

Q: Which hedge fund is a major shareholder of Vaccinex Inc?

Currently, no hedge funds are holding shares in VCNX

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

307 Followers

VCNX Stock Chart & Stats

$0.57

-$0.04(-3.99%)

At close: Jan 08 4:00 PM EST

$0.57

-$0.04(-3.99%)

Day’s Range― - ―

52-Week Range$0.25 - $4.35

Previous CloseN/A

Volume245.00

Average Volume (3M)1.22K

Market Cap

$1.34M

Enterprise Value$5.57M

Total Cash (Recent Filing)$1.11M

Total Debt (Recent Filing)$25.00K

Price to Earnings (P/E)―

Beta2.40

Next Earnings

Nov 17, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,676,637

10 Day Avg. Volume776

30 Day Avg. Volume1,224

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.83

Price to Sales (P/S)3.42

P/FCF Ratio-0.13

Enterprise Value/Market Cap4.16

Enterprise Value/Revenue9.26

Enterprise Value/Gross Profit9.70

Enterprise Value/Ebitda-0.30

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Vaccinex News

Vaccinex to reports new clinical results on pepinemab at ASCO meeting

Vaccinex (VCNX) will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint...

7M ago

VCNX

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

Vaccinex (VCNX) will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to...

8M ago

VCNX

Vaccinex Delays Yearly Report Filing

Vaccinex ( ($VCNX) ) has released a notification of late filing. Vaccinex, Inc., a biotechnology company, has announced...

9M ago

VCNX

Vaccinex to delist common stock from Nasdaq

Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock,...

9M ago

VCNX

Vaccinex receives delisting notification from Nasdaq

Vaccinex (VCNX) announced that on December 16, 2024, the Company received written notice from the Office of General...

12M ago

VCNX

Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year

Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30,...

1y ago

VCNX

Vaccinex provides update on ActivMAb platform

Vaccinex (VCNX) announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil,...

1y ago

VCNX

Vaccinex to preset new biomarker data on HNSCC

Vaccinex (VCNX) announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical...

1y ago

VCNX

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody...

1y ago

VCNX

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase...

1y ago

VCNX

Vaccinex files to sell 1.6M shares of common stock for holders

The company is not selling any shares of common stock under this prospectus and will not receive any...

1y ago

VCNX

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a...

1y ago

VCNX

Vaccinex Provides Update on Alzheimer’s Treatment Trial

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase...

1y ago

VCNX

Vaccinex Completes Key Study Phase for Alzheimer’s Drug

Vaccinex (VCNX) has issued an update. Vaccinex, Inc. has announced the completion of the final patient visit in...

2y ago

VCNX

VCNX FAQ

What was Vaccinex Inc’s price range in the past 12 months?

Vaccinex Inc lowest stock price was $0.25 and its highest was $4.35 in the past 12 months.

What is Vaccinex Inc’s market cap?

Vaccinex Inc’s market cap is $1.34M.

When is Vaccinex Inc’s upcoming earnings report date?

Vaccinex Inc’s upcoming earnings report date is Nov 17, 2025 which is 30 days ago.

How were Vaccinex Inc’s earnings last quarter?

Currently, no data Available

Is Vaccinex Inc overvalued?

According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vaccinex Inc pay dividends?

Vaccinex Inc does not currently pay dividends.

What is Vaccinex Inc’s EPS estimate?

Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vaccinex Inc have?

Vaccinex Inc has 2,676,637 shares outstanding.

What happened to Vaccinex Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vaccinex Inc?

Currently, no hedge funds are holding shares in VCNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.